Design of sequentially randomized trials for testing adaptive treatment strategies.
Semhar B OgbagaberJordan KarpAbdus S WahedPublished in: Statistics in medicine (2015)
An adaptive treatment strategy (ATS) is an outcome-guided algorithm that allows personalized treatment of complex diseases based on patients' disease status and treatment history. Conditions such as AIDS, depression, and cancer usually require several stages of treatment because of the chronic, multifactorial nature of illness progression and management. Sequential multiple assignment randomized (SMAR) designs permit simultaneous inference about multiple ATSs, where patients are sequentially randomized to treatments at different stages depending upon response status. The purpose of the article is to develop a sample size formula to ensure adequate power for comparing two or more ATSs. Based on a Wald-type statistic for comparing multiple ATSs with a continuous endpoint, we develop a sample size formula and test it through simulation studies. We show via simulation that the proposed sample size formula maintains the nominal power. The proposed sample size formula is not applicable to designs with time-to-event endpoints but the formula will be useful for practitioners while designing SMAR trials to compare adaptive treatment strategies.
Keyphrases
- end stage renal disease
- human milk
- newly diagnosed
- primary care
- double blind
- squamous cell carcinoma
- combination therapy
- open label
- clinical trial
- machine learning
- randomized controlled trial
- prognostic factors
- phase iii
- young adults
- preterm infants
- papillary thyroid
- single cell
- deep learning
- low birth weight
- general practice
- neural network